Establishment Labs Holdings Inc. · NASDAQ:ESTA
Establishment Labs — Investor Presentation (December 2020)
28 slides from Establishment Labs's investor presentation, December 2020
Slide 1: Establishment Labs Company Overview December 2020
Establishment Labs Holdings Inc. (NASDAQ: ESTA) COMP ANY OVE R VIEW D E CE MB E R 2020
Slide 2: Safe Harbor and Forward Looking Statements
PROPRIETARY INFORMATION OF ESTABLISHMENT LABS HOLDINGS INC. (“Establishment Labs”) Safe Harbor The information contained in this document is Establishment Labs’ PROPRIETARY INFORMATION and is disclosed in CONFIDENCE. It is the property of Establishment Labs and and shall not be used, disclosed to ot
Slide 3: Company Overview
C) Establishment Labs Company Overview
Slide 4: Establishment Labs
Establishment Labs A global medical technology company Vision – To transform our industry by focusing on women’s health and creating value for all stakeholders Mission – To create safe solutions based on science & user-centric design through collaboration, integrity and respect COMPANY CONFIDENTIAL.
Slide 5: A Global Presence in More Than 80 Countries
A Global Presence in More Than 80 Countries • $90M sales in 2019, a 46% y-o-y increase • ~500 employees • Headquartered in Costa Rica • 2 state-of-the-art manufacturing facilities • Broad patent portfolio • Experienced management team Market Presence Direct Markets Future Pending Markets 5
Slide 6: Investment Attributes
Investment Attributes • The most comprehensive portfolio of breast aesthetics products with a demonstrated safety profile • Market share gains and established leadership positions across many international markets • An exciting pipeline of innovative products to deliver near-term growth • Planned en
Slide 7: Reinventing Breast Aesthetics and Reconstruction
Reinventing Breast Aesthetics and Reconstruction
Slide 8: Breast Aesthetics Market Dynamics
Breast Aesthetics Market Dynamics • Relatively little innovation in implant technology; products sold today date back to 1990s & earlier • Large competitors focused on other segments • Many very small competitors, often regionally focused • An ever-changing regulatory landscape • Breast augmentation
Slide 9: The Motiva Difference
The Motiva Difference ® A new surface technology that lowered complication rates… • SmoothSilk’s nanosurface features optimize biocompatibility • Promotes reduction in capsular contracture …while offering a better aesthetic result. • Proprietary silicone gel family offers natural tactile feel and mo
Slide 10: What Makes Motiva Implants Different? A new silicone shell
What Makes Motiva Implants Different? ® 1 A new silicone shell • TrueMonobloc® • High durability under stress • Easy-to-insert performance shell • Allows for smaller incisions and smaller scars 10
Slide 11: What Makes Motiva Implants Different? A new silicone gel family
What Makes Motiva Implants Different? ® 2 A new silicone gel family • ProgressiveGel® PLUS & ULTIMA® • Unique elastic, viscous and cohesive properties • Custom made and proprietary • Natural tactile feel and movement ProgressiveGel® PLUS ProgressiveGel® ULTIMA® Provides shape-adaptive response (lyin
Slide 12: What Makes Motiva Implants Different? New safety features
What Makes Motiva Implants Different? ® 3 New safety features • Q Inside® (FDA cleared) • Embedded RFID microtransponder • Non-invasive read of electronic serial number associated with implant data • Enhances product safety and patient peace of mind 12
Slide 13: What Makes Motiva Implants Different? A new implant surface
What Makes Motiva Implants Different? ® 4 A new implant surface • SmoothSilk® / SilkSurface® • Nanosurface features optimize biocompatibility through cell adhesion properties • Patent protected • Promotes reduction in capsular contracture 13
Slide 14: SmoothSilk Technology Offers Substantial Product Differentiation
SmoothSilk Technology Offers Substantial Product ® Differentiation Breast implants classification according to its surface International Organization for Standardization (ISO-14607:2018) Establishment Labs data generated internally per ISO-14607:2018 TS-17-026.R Surface Characterization Report of di
Slide 15: Motiva's Unique Surface Demonstrates Positive Clinical Outcomes
Motiva’s Unique Surface Demonstrates Positive Clinical Outcomes 15
Slide 16: Robust Safety and Performance Data
Robust Safety and Performance Data Innovative technology, and a strong foundation of science and research, has resulted in nearly 1.3 million Motiva Implants® placed worldwide* * Placements outside of the U.S. and China 16
Slide 17: Lack of Innovation in the Breast Implant Industry
Lack of Innovation in the Breast Implant Industry Each of these prospective studies was conducted at multiple sites in the United States and Results from all surgery Sientra Allergan Mentor submitted by each of these companies as their core study supporting approval, as that cohorts 5-Year 6-Year 6-
Slide 18: How We Drive Growth
Establishment Labs How We Drive Growth Entering Expanding Launching new our direct new and markets sales model innovative products
Slide 19: Approvals in China and the U.S. Would Triple Addressable Market Opportunity
Approvals in China and the U.S. Would Triple Addressable Market Opportunity China United States • ~$150-$200M* market • ~½ of the global market and growing rapidly • ~80% of market is • Third largest affluent aesthetic procedures population globally Currently Addressable Future • Enrollment in aesth
Slide 20: New Products Represent Opportunities for Additional Growth
New Products Represent Opportunities for Additional Growth • Motiva Flora unlocks the breast reconstruction segment The only tissue expander for use alongside MRI scanning Broad commercial launch in Europe in early 2021 • Motiva Ergonomix2 can extend market share gains The next-generation of b
Slide 21: Motiva Mia – A Disruptive Technology
Motiva Mia – A Disruptive Technology • Designed for women seeking a one-cup size up augmentation in a simple, minimally invasive procedure • Annually, as many as 1.9 million* women would consider a minimally invasive procedure • Offers augmentation considerably more subtle in sizing and approach N
Slide 22: Our Digital Resources Connect Surgeons and Patients
Our Digital Resources Connect Surgeons and Patients 22
Slide 23: Financial Highlights and Outlook
Financial Highlights and Outlook
Slide 24: Strong Financial Performance
Strong Financial Performance Revenue Gross Profit Margin $ in millions $89.6 61% $61.2 59% 51% $34.7 2017 2018 2019 2017 2018 2019 Q1 Q2 Q3 Q4 Column1 24
Slide 25: A Strong Financial Position and Disciplined Expense Control in 2020
A Strong Financial Position and Disciplined Expense Control in 2020 • Q3 2020 sales of $22.8M, above guidance range Strong recovery from pandemic well underway Issued full year revenue guidance of $80-$82M* • Reduced Q3 2020 operating expenses by 23% over Q3 2019 Low operating cash burn of $3M
Slide 26: Committed to Sustainability
Committed to Sustainability • Our CSR program is aligned with 3 United Nations Sustainable Development Goals (SDGs) Well-Being (Goal 3) Women’s Empowerment (Goal 5) Environment & Sustainability (Goal 13) • Signatory of UN’s Women’s Empowerment Principles • Headquarters & manufacturing faciliti
Slide 27: Establishment Labs is Well-Positioned for Continued Growth and Success
Establishment Labs is Well-Positioned for Continued Growth and Success • The most comprehensive product portfolio in breast aesthetics market • Demonstrated safety profile • Gaining market share • Innovative product pipeline • Sizable new market opportunities • Disciplined financial management • Ent
Slide 28: Committed to women's health and well-being
Committed to women’s health and well-being establishmentlabs.com
Establishment Labs Holdings — Investor Presentation (December 2020) on 6ix